| scholarly article | Q13442814 |
| P50 | author | Catharien M. Hilkens | Q74316716 |
| John D Isaacs | Q56408288 | ||
| P2093 | author name string | J D Isaacs | |
| C M U Hilkens | |||
| P2860 | cites work | Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance | Q80358513 |
| Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB | Q80544759 | ||
| Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells | Q80597339 | ||
| IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction--a comparative study of human clinical-applicable DC | Q83191176 | ||
| MicroRNA-23b promotes tolerogenic properties of dendritic cells in vitro through inhibiting Notch1/NF-κB signalling pathways | Q83197648 | ||
| Weak CD4+ T-cell responses to citrullinated vimentin in rheumatoid arthritis patients carrying HLA-DR9 alleles | Q84571482 | ||
| The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and β-actin | Q87417540 | ||
| Biologics for rheumatoid arthritis: an overview of Cochrane reviews | Q24240731 | ||
| Biologics for rheumatoid arthritis: an overview of Cochrane reviews | Q24240891 | ||
| Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 | Q24634871 | ||
| Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity | Q24643886 | ||
| Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+ T cells from patients with rheumatoid arthritis | Q24798549 | ||
| Induction of tolerance by IL-10-treated dendritic cells | Q73873437 | ||
| Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival | Q73939259 | ||
| Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis | Q74410146 | ||
| Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10 | Q78804319 | ||
| Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients | Q80034808 | ||
| 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation | Q28370605 | ||
| Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells | Q28378178 | ||
| A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism | Q29614266 | ||
| Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid | Q29615586 | ||
| Tolerogenic dendritic cells | Q29618755 | ||
| Regulatory T cells: mechanisms of differentiation and function | Q29620731 | ||
| Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo | Q30080006 | ||
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 | ||
| T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal | Q33774232 | ||
| Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis | Q33832421 | ||
| Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance | Q33897693 | ||
| Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. | Q34193317 | ||
| Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells | Q34540019 | ||
| Peptides presented by HLA-DR molecules in synovia of patients with rheumatoid arthritis or antibiotic-refractory Lyme arthritis | Q34616781 | ||
| How tolerogenic dendritic cells induce regulatory T cells | Q34631825 | ||
| A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. | Q34634834 | ||
| Dendritic cell control of tolerogenic responses | Q34982085 | ||
| Dendritic cells in immunity and tolerance-do they display opposite functions? | Q35181775 | ||
| Tolerogenic dendritic cells and their role in transplantation. | Q35341379 | ||
| Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation | Q35640630 | ||
| The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli | Q36368355 | ||
| Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussi | Q36369855 | ||
| Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease | Q36375982 | ||
| Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. | Q36379002 | ||
| CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis | Q36524672 | ||
| Plasmacytoid dendritic cells mediate oral tolerance | Q36534744 | ||
| Determination of T-cell fate by dendritic cells | Q37125939 | ||
| Activation of dendritic cells by toll-like receptors and C-type lectins | Q37334043 | ||
| Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists | Q37633537 | ||
| Development of dendritic cell-based immunotherapy for autoimmunity | Q37701864 | ||
| Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. | Q37705125 | ||
| Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? | Q37908887 | ||
| Human dendritic cell deficiency: the missing ID? | Q37919720 | ||
| Induced CD4+Foxp3+ regulatory T cells in immune tolerance | Q37973769 | ||
| Tolerogenic dendritic cells: applications for solid organ transplantation | Q37974050 | ||
| The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells | Q38008355 | ||
| Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides | Q38309722 | ||
| Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis | Q39946625 | ||
| Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression | Q40402602 | ||
| Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors | Q40532147 | ||
| Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. | Q40647086 | ||
| A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization | Q40700194 | ||
| Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. | Q41180997 | ||
| Cartilage proteoglycan aggrecan epitopes induce proinflammatory autoreactive T-cell responses in rheumatoid arthritis and osteoarthritis | Q41440061 | ||
| Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells | Q41754216 | ||
| High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering. | Q41987472 | ||
| LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. | Q42110748 | ||
| HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets | Q42412117 | ||
| Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. | Q42608288 | ||
| Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells | Q42944333 | ||
| Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy | Q42971266 | ||
| Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis | Q43205831 | ||
| L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance | Q43874047 | ||
| Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis | Q43904319 | ||
| Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection | Q44422799 | ||
| The changing face of rheumatoid arthritis: sustained remission for all? | Q44508845 | ||
| Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. | Q44539418 | ||
| T cells signaled by NF-kappa B- dendritic cells are sensitized not anergic to subsequent activation | Q44987457 | ||
| Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients | Q45862110 | ||
| Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice | Q45879284 | ||
| Targeted lymphoid homing of dendritic cells is required for prolongation of allograft survival | Q46108818 | ||
| Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. | Q46499903 | ||
| Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages | Q47566959 | ||
| Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells | Q47810559 | ||
| Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results | Q50047316 | ||
| Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. | Q51567175 | ||
| A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. | Q52852039 | ||
| Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. | Q52914622 | ||
| Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. | Q54348864 | ||
| Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. | Q54570858 | ||
| Prolongation of rat intestinal allograft survival by administration of donor interleukin-12 p35-silenced bone marrow-derived dendritic cells. | Q54655361 | ||
| Dendritic Cells Matured With TNF can be Further Activated In Vitro and After Subcutaneous Injection In Vivo Which Converts Their Tolerogenicity Into Immunogenicity | Q56689252 | ||
| "Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig | Q56901846 | ||
| CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity | Q56904531 | ||
| Identification of citrullinated vimentin peptides as T cell epitopes in HLAâ DR4â positive patients with rheumatoid arthritis | Q58234841 | ||
| Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells | Q58234914 | ||
| Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses | Q60061990 | ||
| Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis | Q60061992 | ||
| Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients | Q61656600 | ||
| Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL | Q64378360 | ||
| Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4 | Q64380123 | ||
| The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium | Q67466174 | ||
| Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells | Q71614430 | ||
| Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse | Q73153290 | ||
| Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival | Q73289641 | ||
| P433 | issue | 2 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 148-157 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? | |
| P478 | volume | 172 |
| Q64106840 | 1,25-Dihydroxyvitamin D Restrains CD4 T Cell Priming Ability of CD11c Dendritic Cells by Upregulating Expression of CD31 |
| Q36292610 | 1,25-Dihydroxyvitamin D3-Conditioned CD11c+ Dendritic Cells are Effective Initiators of CNS Autoimmune Disease. |
| Q39035161 | Adoptive cell transfer in autoimmune hepatitis |
| Q38960509 | Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles |
| Q39431371 | Antigen-specific immunotherapies in rheumatic diseases |
| Q48004729 | Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype. |
| Q37604510 | Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis |
| Q54211751 | Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis. |
| Q64063659 | CD38 Deficiency Downregulates the Onset and Pathogenesis of Collagen-Induced Arthritis through the NF-B Pathway |
| Q38729042 | Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy. |
| Q26773299 | Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort |
| Q35843248 | DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice |
| Q26764858 | Dendritic Cell-based Immunotherapy for Rheumatoid Arthritis: from Bench to Bedside |
| Q42738684 | Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2. |
| Q21284774 | Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation |
| Q38281782 | Dendritic cell-based vaccine research against cancer. |
| Q47550123 | Directed Differentiation of Human Induced Pluripotent Stem Cells into Dendritic Cells Displaying Tolerogenic Properties and Resembling the CD141+ Subset |
| Q87155857 | Effect of bone marrow-derived CD11b(+)F4/80 (+) immature dendritic cells on the balance between pro-inflammatory and anti-inflammatory cytokines in DBA/1 mice with collagen-induced arthritis |
| Q38188862 | Emerging immunotherapies for rheumatoid arthritis. |
| Q53818876 | Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation. |
| Q33841419 | Future therapeutic targets in rheumatoid arthritis? |
| Q26779413 | Gene Expression Profiling of Human Monocyte-derived Dendritic Cells - Searching for Molecular Regulators of Tolerogenicity |
| Q45942932 | Generating a Tolerogenic Cell Therapy Knowledge Graph from Literature. |
| Q35571114 | Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer |
| Q26764855 | Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications |
| Q47348999 | Generation of regulatory dendritic cells after treatment with paeoniflorin |
| Q64110634 | Heat Shock Proteins Can Be Surrogate Autoantigens for Induction of Antigen Specific Therapeutic Tolerance in Rheumatoid Arthritis |
| Q38895446 | Heat shock proteins and their immunomodulatory role in inflammatory arthritis |
| Q58831417 | Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients |
| Q39245827 | In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance. |
| Q47618676 | Induction of porcine-specific regulatory T cells with high specificity and expression of IL-10 and TGF-β1 using baboon-derived tolerogenic dendritic cells. |
| Q37670174 | It's time to bring dendritic cell therapy to type 1 diabetes. |
| Q41766647 | Lipopolysaccharide-primed heterotolerant dendritic cells suppress experimental autoimmune uveoretinitis by multiple mechanisms |
| Q96134790 | Marshallagia marshalli Antigen Strengthens Dendritic Cell Mediated T Lymphocyte Regulation on Asthmatic Patients |
| Q28385947 | Metabolic control of dendritic cell activation and function: recent advances and clinical implications |
| Q26765348 | Metabolism Is Central to Tolerogenic Dendritic Cell Function |
| Q28596281 | Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies |
| Q36968028 | Myeloid deletion of SIRT1 suppresses collagen-induced arthritis in mice by modulating dendritic cell maturation |
| Q34379951 | Orchestration of transplantation tolerance by regulatory dendritic cell therapy or in-situ targeting of dendritic cells |
| Q57288028 | Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development |
| Q94219607 | Potential Vaccines for Treating Crohn's Disease |
| Q38794663 | Recent advances and current state of immunotherapy in systemic lupus erythematosus |
| Q27025996 | Regulatory dendritic cell therapy: from rodents to clinical application |
| Q92303151 | Regulatory dendritic cells for human organ transplantation |
| Q26866216 | Regulatory dendritic cells for immunotherapy in immunologic diseases |
| Q57790413 | Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation |
| Q49906660 | Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier In Vitro via the Introduction of De Novo C-C Chemokine Receptor 5 Expression Using Messenger RNA Electroporation. |
| Q40095092 | Targeting of tolerogenic dendritic cells towards heat shock proteins: a novel therapeutic strategy for autoimmune diseases? |
| Q37156931 | The Effect of Traditional Chinese Formula Danchaiheji on the Differentiation of Regulatory Dendritic Cells |
| Q30317628 | The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape |
| Q59802848 | The effect of the cholinergic anti-inflammatory pathway on collagen-induced arthritis involves the modulation of dendritic cell differentiation |
| Q28080019 | The thymus and rheumatology: should we care? |
| Q38169713 | Therapeutic potential of tolerogenic dendritic cells in IBD: from animal models to clinical application |
| Q58615311 | Tolerising cellular therapies: what is their promise for autoimmune disease? |
| Q26776126 | Tolerogenic Dendritic Cells for Regulatory T Cell Induction in Man |
| Q45892619 | Tolerogenic dendritic cells are efficiently generated using minocycline and dexamethasone |
| Q38800903 | Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-β1. |
| Q38339535 | Tolerogenic dendritic cells: role and therapeutic implications in systemic lupus erythematosus. |
| Q49376559 | Trichinella spiralis Excretory-Secretory Products Induce Tolerogenic Properties in Human Dendritic Cells via Toll-Like Receptors 2 and 4. |
Search more.